316 related articles for article (PubMed ID: 26614903)
1. BRAF inhibitor therapy in HCL.
Dietrich S; Zenz T
Best Pract Res Clin Haematol; 2015 Dec; 28(4):246-52. PubMed ID: 26614903
[TBL] [Abstract][Full Text] [Related]
2. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
[TBL] [Abstract][Full Text] [Related]
3. Hairy cell leukemia: update and current therapeutic approach.
Salam L; Abdel-Wahab O
Curr Opin Hematol; 2015 Jul; 22(4):355-61. PubMed ID: 26049757
[TBL] [Abstract][Full Text] [Related]
4. Hairy cell leukemia: Past, present and future.
Getta BM; Park JH; Tallman MS
Best Pract Res Clin Haematol; 2015 Dec; 28(4):269-72. PubMed ID: 26614906
[TBL] [Abstract][Full Text] [Related]
5. BRAF inhibition in refractory hairy-cell leukemia.
Dietrich S; Glimm H; Andrulis M; von Kalle C; Ho AD; Zenz T
N Engl J Med; 2012 May; 366(21):2038-40. PubMed ID: 22621641
[No Abstract] [Full Text] [Related]
6. BRAF in the cross-hairs.
Geyer MB; Abdel-Wahab O; Tallman MS
Expert Rev Hematol; 2019 Mar; 12(3):183-193. PubMed ID: 30782032
[TBL] [Abstract][Full Text] [Related]
7. Dabrafenib therapy for advanced melanoma.
Trinh VA; Davis JE; Anderson JE; Kim KB
Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
[TBL] [Abstract][Full Text] [Related]
8. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
Vergote V; Dierickx D; Janssens A; Verhoef G; Tousseyn T; Vandenberghe P; Wolter P; Delforge M
Ann Hematol; 2014 Dec; 93(12):2087-9. PubMed ID: 24863690
[No Abstract] [Full Text] [Related]
9. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
Blachly JS; Lozanski G; Lucas DM; Grever MR; Kendra K; Andritsos LA
J Natl Compr Canc Netw; 2015 Jan; 13(1):9-13; quiz 13. PubMed ID: 25583765
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
Gibney GT; Zager JS
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
[TBL] [Abstract][Full Text] [Related]
11. Historical overview of hairy cell leukemia.
Andritsos LA; Grever MR
Best Pract Res Clin Haematol; 2015 Dec; 28(4):166-74. PubMed ID: 26614894
[TBL] [Abstract][Full Text] [Related]
12. B-Raf Inhibition in the Clinic: Present and Future.
Fiskus W; Mitsiades N
Annu Rev Med; 2016; 67():29-43. PubMed ID: 26768236
[TBL] [Abstract][Full Text] [Related]
13. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
14. Resistance to BRAF-targeted therapy in melanoma.
Sullivan RJ; Flaherty KT
Eur J Cancer; 2013 Apr; 49(6):1297-304. PubMed ID: 23290787
[TBL] [Abstract][Full Text] [Related]
15. New insights in the management of patients with hairy cell leukemia.
Cornet E; Damaj G; Troussard X
Curr Opin Oncol; 2015 Sep; 27(5):371-6. PubMed ID: 26154707
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E mutation in hairy cell leukemia: from bench to bedside.
Falini B; Martelli MP; Tiacci E
Blood; 2016 Oct; 128(15):1918-1927. PubMed ID: 27554081
[TBL] [Abstract][Full Text] [Related]
17. New RAF kinase inhibitors in cancer therapy.
Martin-Liberal J; Larkin J
Expert Opin Pharmacother; 2014 Jun; 15(9):1235-45. PubMed ID: 24766074
[TBL] [Abstract][Full Text] [Related]
18. Hairy cell leukemia.
Dearden C
Best Pract Res Clin Haematol; 2015 Dec; 28(4):163-5. PubMed ID: 26614893
[No Abstract] [Full Text] [Related]
19. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.
Peyrade F; Re D; Ginet C; Gastaud L; Allegra M; Ballotti R; Thyss A; Zenz T; Auberger P; Robert G
Haematologica; 2013 Feb; 98(2):e20-2. PubMed ID: 23300174
[No Abstract] [Full Text] [Related]
20. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
Tiacci E; Park JH; De Carolis L; Chung SS; Broccoli A; Scott S; Zaja F; Devlin S; Pulsoni A; Chung YR; Cimminiello M; Kim E; Rossi D; Stone RM; Motta G; Saven A; Varettoni M; Altman JK; Anastasia A; Grever MR; Ambrosetti A; Rai KR; Fraticelli V; Lacouture ME; Carella AM; Levine RL; Leoni P; Rambaldi A; Falzetti F; Ascani S; Capponi M; Martelli MP; Park CY; Pileri SA; Rosen N; FoĆ R; Berger MF; Zinzani PL; Abdel-Wahab O; Falini B; Tallman MS
N Engl J Med; 2015 Oct; 373(18):1733-47. PubMed ID: 26352686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]